Nanocarriers for Anticancer Drug Targeting: Recent Trends and Challenges

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Nanocarriers are nanostructured vehicles for targeted anticancer drug delivery.
• They offer improved bioavailability, circulation time, and tumor accumulation over conventional methods.
• Functionalization allows tailoring pharmacokinetics for enhanced cancer therapy.

Purpose of the Study:

• To review the role of tumor vasculature in nanocarrier-based drug targeting.
• To explore advanced cancer immunotherapy approaches and their clinical development.
• To address challenges and translational obstacles of nanocarriers in cancer treatment.

Main Methods:

• Review of literature on nanocarriers for anticancer drug delivery.
• Analysis of passive and active targeting strategies utilizing tumor vasculature.
• Exploration of organic, inorganic, and hybrid nanocarrier types.
• Examination of cancer immunotherapy advancements and clinical trials.

Main Results:

• Nanocarriers improve drug delivery efficacy and therapeutic outcomes in cancer treatment.
• Tumor vasculature plays a critical role in both passive and active nanocarrier targeting.
• Advanced immunotherapies offer new treatment options for intractable cancers.
• Several nanocarriers are approved or in clinical development for cancer therapy.

Conclusions:

• Nanocarriers are vital tools in modern cancer therapy, improving drug delivery and treatment effectiveness.
• Understanding tumor vasculature is key to optimizing nanocarrier targeting strategies.
• Continued research and development in nanocarriers and immunotherapies hold significant promise for cancer patients.
• Addressing translational challenges is crucial for the clinical success of nanocarrier-based cancer treatments.